newsfilter
← Latest News
GlobeNewswire·

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

  • ProMIS Neurosciences Inc. announced participation in five September 2026 investor conferences & key events in New York, NY.
  • The company will present at the Cantor Global Healthcare Conference (Sept 9), Moody Capital Disruptive Growth & Life Sciences Conference (Sept 10), H.C. Wainwright 28th Annual Global Investment Conference (Sept 15), Roth Healthcare Opportunities Conference (Sept 29), & mark World Alzheimer's Day at the Nasdaq Tower (Sept 21).
  • Executives Neil Warma, Dr. Larry Altstiel, & Carie Pierce will discuss the EpiSelect™ platform, the company's therapeutic approach for neurodegenerative diseases, & lead candidate PMN310 in the ongoing PRECISE-AD Phase 1b trial.
  • Blinded 6-month interim data from the fully enrolled PRECISE-AD Phase 1b trial in early Alzheimer's disease was reported in July 2026.
  • Topline 12-month data for the PRECISE-AD trial is anticipated in early 2027.
  • Webcast replays of upcoming presentations & the interim data webinar will be available on the company's investor relations website.
  • ProMIS Neurosciences is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with an additional office in Toronto, Ontario.